预约演示
更新于：2025-02-07
Flurbiprofen Sodium
氟比洛芬钠
更新于：2025-02-07
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1986-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H13FNaO2 |
InChIKeyCGCMNXTUJNJYIY-UHFFFAOYSA-N |
CAS号56767-76-1 |
关联
2
项与 氟比洛芬钠 相关的临床试验ISRCTN10047986
Pain-relieving plaster versus flurbiprofen cataplasms in terms of pain, stiffness, functional activities, joint swelling, quality of life, and safety for knee osteoarthritis treatment: a multi-center, randomized, controlled, non-inferiority clinical trial.
CTR20212329
评估受试制剂氟比洛芬凝胶贴膏（规格：40mg）与参比制剂（泽普思® ）（规格：40mg）在健康成年受试者外用条件下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究。
100 项与 氟比洛芬钠 相关的临床结果
登录后查看更多信息
100 项与 氟比洛芬钠 相关的转化医学
登录后查看更多信息
100 项与 氟比洛芬钠 相关的专利（医药）
登录后查看更多信息
4,224
项与 氟比洛芬钠 相关的文献（医药）2025-04-01SEPARATION AND PURIFICATION TECHNOLOGY
Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography
作者: Plachka, Katerina ; Gazarkova, Tatana ; Plachká, Kateřina ; Pilarova, Veronika ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána
The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH3, and methanol + 2 % H2O, in CO2.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.
2025-02-03ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Redox‐Neutral Carboxylation of Benzylic Tertiary C−H Bonds with Carbon Dioxide
Article
作者: Jiang, Liang‐Liang ; Zhang, Shan‐Shan ; Li, Hao‐Yuan ; Yuan, Pan‐Feng ; Li, Jun‐Li ; Zhong, Jian‐Ji ; Yang, Xiu‐Long ; Meng, Qing‐Yuan ; Zhu, Can‐Ming ; Yang, Zhao
Abstract:
The direct catalytic carboxylation of benzylic tertiary C−H bonds with CO2 for the synthesis of all‐carbon quaternary carboxylic acids represents a significant challenge. Here, we present a redox‐neutral approach to address this difficulty by leveraging the synergistic interplay between photocatalysis and cascade hydrogen abstraction cycles. Remarkably, this strategy eliminates the need for sacrificial electron donors, electron acceptors, or stoichiometric additives, offering enhanced atom economy and environmental sustainability. It is particular that the combination of α‐amino alkyl radicals with sulfur radicals generated in situ from the decomposition of DMSO was employed to realize the abstraction of benzylic tertiary C−H bonds. Our method enables the direct synthesis of a diverse array of benzylic quaternary carboxylic acids with excellent functional group tolerance as well as the derivatization of bioactive molecules and the gram‐scale synthesis of pharmaceuticals under mild reaction conditions.
2025-02-01JOURNAL OF MOLECULAR STRUCTURE
Flurbiprofen clubbed schiff's base derivatives as potent anticancer agents: In Vitro and In Silico approach towards breast cancer
作者: Al-Harrasi, Ahmed ; Ahmad, Manzoor ; Zainab ; Ali, Mumtaz ; Khan, Faizullah ; Islam, Wassem Ul ; Alam, Aftab ; Rehman, Najeeb Ur ; Aziz, Shahkaar ; Elhenawy, Ahmed A.
In this work, we are reporting nineteen hydrazone-Schiff base derivatives (2a-2l and 3a-3g), containing flurbiprofen drug nucleus.The synthesized products were structurally elucidated through 1H, 13C-NMR and HR-ESI-MS spectroscopic techniques and finally tested for in vitro anti-cancer activity.Among the synthetic series, 2f, 2g, 3g, 3b, and 2e attributed the higher inhibitory potential against the breast cancer cell line (MDA-MB-231) having IC50 values of 21.0 ± 0.4, 21.8 ± 0.2, 27.1 ± 0.3, 28.8 ± 0.3, and 29.6 ± 0.3 μM resp.However, the remaining derivatives attributed good to less active.DFT was used to calculate frontier MO of (2a-h, j-l, and 3a-d) including HOMO which concentrated on the substituents aromatic ring, and LUMO focused over flurbiprofen and hydrazide fragments, that indicate the charge transfer from mol. to biol. media.The reactivity indexes suggested the most active 2f (IC50 = 21.0 ± 0.4 μM) and 2g (IC50 = 21.8 ± 0.2 μM) showed higher indexes reactivity namely σ, χ, and ω than lowest active 2g; this relation inversely for Eg, η, and IP. 2a-l had more electrophilic character and higher acceptance ability for biol. targets than compounds (3a-g).The MEP map indicated the electron d. distribution of 2a-l was more dispersed than that of 3a-g, indicating potential biol. activities and are chem. reactive zone suitable for drug action.The docking study contributed to the anal. of cytotoxicity for investigated compounds
100 项与 氟比洛芬钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 强直性脊柱炎 | 中国 | 1998-01-01 | |
| 骨关节炎 | 中国 | 1998-01-01 | |
| 疼痛 | 中国 | 1998-01-01 | |
| 类风湿关节炎 | 中国 | 1998-01-01 | |
| 瞳孔缩小 | 美国 | 1986-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床3期 | 中国 | 2020-03-31 | |
| 膝关节炎 | 临床3期 | 中国 | 2020-03-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用